DENYES NANCY 4
4 · aTYR PHARMA INC · Filed Feb 6, 2023
Insider Transaction Report
Form 4
aTYR PHARMA INCLIFE
DENYES NANCY
General Counsel
Transactions
- Exercise/Conversion
Common stock
2023-02-03+2,688→ 7,079 total - Exercise/Conversion
Restricted Stock Unit
2023-02-03−2,688→ 8,062 total→ Common Stock (2,688 underlying)
Footnotes (4)
- [F1]Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
- [F2]Restricted stock units convert into common stock on a one-for-one basis.
- [F3]Includes 944 shares acquired under that Company's 2015 Employee Stock Purchase Plan on November 15, 2022.
- [F4]The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.